ICML 2019 | CHECKMATE 205: Does nivolumab improve the long-term outcomes of patients with advanced stage cHL?

During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Stephen Ansell from Mayo Clinic, Rochester, US, about the CHECKMATE 205 trial. In this interview, Stephen Ansell discusses whether nivolumab improves the long-term outcomes of patients with advanced stage classical Hodgkin lymphoma (cHL).

Initial results of the trial showed a very good progression-free survival (PFS), with updated results showing a two-year PFS of 83%. Despite having dropped from the nine-month PFS, Stephen Ansell mentioned that the results were still promising, with exciting results ahead for novel agents that are being used alongside chemotherapy.